Editorials

Expanding treatment options by selectively targeting the cytokine storm with ruxolitinib in primary hemophagocytic lymphohistiocytosis

Section of Clinical Immunology, Department of Internal Medicine and Immunology, Erasmus University Medical Center Rotterdam, Rotterdam
Haematologica Early view Sep 7, 2023 https://doi.org/10.3324/haematol.2023.283915